报告期内，公司经营业绩受以下因素综合影响：(1)医保控费政策持续深化，核心产品安佳因?多次降 价，公司整体营业收入较上年同期降幅明显；(2)为推进新获批产品的市场准入与渠道建设，公司阶段 性加大商业化投入，销售费用有所增长；(3)公司持续推进多管线并行研发，多个项目处于临床研究中 后期，研发投入保持高位，对当期利润产生影响，2025年公司将由盈转亏。 格隆汇2月27日丨神州细胞(688520.SH)发布2025年度业绩快报，报告期内，公司实现营业总收入15.60亿 元，同比减少37.91%；实现归属于母公司所有者的净利润-55,329.37万元，归属于母公司所有者的扣除 非经常性损益的净利润-53,639.05万元，较上年同期相比由盈转亏。 ...

（文章来源：证券日报） 证券日报网讯 2月27日，神州细胞发布业绩快报称，公司2025年实现营业总收入156015.30万元，同比减 少37.91%；归属于母公司所有者的净利润为-55329.37万元。 ...

证券代码：688520 证券简称：神州细胞 公告编号：2026-003 北京神州细胞生物技术集团股份公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以北京神州细胞生物技术集团股份公司（以下简称"公司"）2025 年年度报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 156,015.30 | 251,270.81 | -37.91 | | 营业利润 | -42,734.88 | 56,840.55 | 不适用 | | 利润总额 | -55,462.11 | 11,234.90 | 不适用 | | 归属于母公司所有者的净利润 | -55,329.37 | 11,195.11 | 不适用 | | 归属于母公司所有者的扣除非经常性损益 的净利润 ...

神州细胞公告称，2025年度营业总收入156,015.30万元，同比减少37.91%；归属于母公司所有者的净利 润-55,329.37万元，由盈转亏。报告期末，总资产383,328.43万元，较期初增加16.73%；归属于母公司的 所有者权益13,956.18万元，较期初减少0.95%。业绩变动主要因医保控费、核心产品降价、商业化投入 及研发投入增加。数据为初步核算，未经审计，以年报为准。 ...

Core Viewpoint - Shenzhou Cell forecasts a net profit loss of 520 million to 580 million yuan for 2025, primarily due to significant revenue decline from its core product Anjiah, impacted by medical insurance cost control and price reductions [1] Financial Performance - The company anticipates a net profit loss of 503 million to 563 million yuan after excluding non-recurring items, with R&D investment projected between 830 million to 870 million yuan [1] - In the Q3 2025 report, revenue decreased by 32.27% year-on-year, with a net profit loss of 251 million yuan and a debt ratio of 101.46% [1] Recent Developments - During an institutional survey, Shenzhou Cell disclosed that several products (e.g., SCT1000, SCT650C, SCTB14) have entered or are planned to advance to Phase III clinical trials, with some potentially entering the registration research phase in 2026 [2] - The company plans to advance several new product IND applications this year and considers overseas business development as a medium to long-term strategy, although specific transactions remain uncertain [2] Stock Performance - Over the past seven trading days, Shenzhou Cell's stock price has declined by 1.55%, with a price range fluctuation of 4.98% [3] - The latest closing price is 39.38 yuan, with trading volume gradually decreasing and turnover rate maintained between 0.24% and 0.46% [3] - The stock has underperformed compared to the overall decline in the pharmaceutical and biotechnology sector [3]

Group 1 - The company, ShenZhou Cell, has a strong research and development capability and plans to advance several product applications for IND this year [2]

Group 1 - The company, ShenZhou Cell, has received approval for a private placement registration as of January 2026, allowing it to issue shares worth up to 900 million RMB [2] - The controlling shareholder plans to subscribe for no more than 900 million RMB of the company's shares [2] - The company intends to initiate and complete the issuance as soon as possible, with further updates to be provided in subsequent announcements [2]

Group 1 - The company, ShenZhou Cell, has indicated that it will prioritize business development (BD) as part of its medium to long-term strategic plan [2] - The company is actively seeking external BD opportunities for its products, although the specifics of any potential transactions remain uncertain and will be subject to formal announcements [2]

Core Viewpoint - The sales of Anjiahin® are expected to decline significantly by 2025 due to several factors, including medical insurance cost control and substantial price reductions initiated by the company in response to national healthcare policies [1] Group 1: Sales and Market Impact - The decline in Anjiahin® sales is primarily influenced by the reduction in patient usage resulting from medical insurance cost control measures [1] - Starting from the third quarter of 2025, Anjiahin® will undergo significant price cuts to align with the national healthcare bureau's initiatives, aiming to make the medication more accessible to patients [1] Group 2: Treatment Guidelines and Patient Care - The revised "Chinese Guidelines for Hemophilia Treatment (2025 Edition)" has redefined treatment approaches for coagulation disorders, shifting from traditional preventive treatment to regular replacement therapy and from on-demand treatment to temporary replacement therapy [1] - The medical community is emphasizing the importance of preventive treatment, and the company hopes that adult patients will receive similar protections as pediatric patients [1] - The company anticipates that the recombinant factor VIII will receive equal treatment as blood-derived factor VIII in the future [1]

Group 1 - The core viewpoint of the article highlights a significant decline in sales of the product Anjiaan® in 2025, attributed to several factors including medical insurance cost control leading to reduced patient usage [2] - The company has implemented a substantial price reduction for Anjiaan® starting from the third quarter of 2025 in response to the National Medical Insurance Administration's call, aiming to benefit patients and improve their survival conditions [2] - The revised "Guidelines for the Treatment of Hemophilia in China (2025 Edition)" has redefined treatment approaches for coagulation disorders, emphasizing the importance of preventive treatment and calling for better protection for adult patients similar to that of children [2]